Thierry Fumeaux: From Efficacy to Effectiveness – The Value of Real-World Evidence
Thierry Fumeaux, Cantonal Physician – Vaud at Directorate General of Health, Vaud – DSAS, shared a post on LinkedIn about a recent article by Yu Yang et al., published in Annals of Internal Medicine, adding:
“RCTs tell us whether a drug can work under controlled conditions. Real-world data tell us whether this added value actually translates into better outcomes once the drug is widely used.
This study is a good example: in patients with atrial fibrillation and mitral stenosis, DOACs were associated with a higher 1-year risk of ischemic stroke than warfarin, despite no significant difference in bleeding or mortality.
Interestingly, they were also associated with a lower risk of myocardial infarction, illustrating how real-world effectiveness may differ across clinically relevant outcomes.
Market access should therefore not be the end of evaluation. Systematic post-market real-world evidence is essential to confirm — or challenge — the value suggested by clinical trials.
From efficacy to effectiveness: that is where the real value of innovation is ultimately measured.”
Title: Real-World Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Mitral Stenosis: A Target Trial Emulation
Authors: Yu Yang, Chin-Yao Shen, Michael Chun-Yuan Cheng, Wei Kang, Philip C.M. Au, Vincent K.C. Yan, Huei-Kai Huang, Chun Ka Wong, Kai Hang Yiu, Hung-Fat Tse, Ching-Lung Cheung, Timothy H. Rainer, Bryan P. Yan, David C.W. Siu, Ian Chi Kei Wong, Edward Chia-Cheng Lai, Esther W.Y. Chan
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 20, 2026, 01:18Sebastian Mafeld: Has 2026 Changed How We Treat Pulmonary Embolism?
-
Sep 20, 2026, 01:16Pall T. Onundarson: DOACs – Monitoring, Tailoring Dose and Identifying Problems
-
Sep 20, 2026, 01:14Said El Shamieh: VEGFA Genetic Variants and Bleeding Risk During Warfarin Therapy
-
Sep 20, 2026, 01:04Omar Danoun: Levetiracetam May Increase Thromboembolic Risk With DOACs
-
Sep 20, 2026, 01:02Mohamed Abo-Aly: Which Antiseizure Medication is Safest for Patients on DOACs?
-
Sep 20, 2026, 00:58Hamza Rafiq: How Does a Deep Vein Thrombosis Become a PE?
-
Sep 20, 2026, 00:50A Shared Platelet Factor 4–Targeted Immune Mechanism in Adenovirus Infection – NEJM
-
Sep 20, 2026, 00:46Julia R. Coleman: Platelet Biology and Sex Differences in the Plasma Milieu at AAST 2026
-
Sep 19, 2026, 18:03Manisha Madkaikar: Clinical, Hematological, and Molecular Features of Sickle β-Thalassemia